US Patent

US12151003 — Stable, concentrated radionuclide complex solutions

Method of Use · Assigned to Advanced Accelerator Applications SA · Expires 2038-07-25 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using a radionuclide complex solution, specifically Lutetium Lu 177 Dotatate, with added stabilizers to prevent degradation.

USPTO Abstract

The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4036 — lutetium-lu-177-dotatate

Patent Metadata

Patent number
US12151003
Jurisdiction
US
Classification
Method of Use
Expires
2038-07-25
Drug substance claim
No
Drug product claim
Yes
Assignee
Advanced Accelerator Applications SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.